Search Results | Blood | American Society of Hematology

1-20 of 1775

2 3 4 5

Sort by

Sort Order Select

Journal Articles

Primary mediastinal Large B-cell Lymphoma

Kerry J. Savage

Blood blood.2020008376.

DOI: https://doi.org/10.1182/blood.2020008376

Published: 2021

Includes: Supplemental data

Journal Articles

Clonal evolution of acute myeloid leukemia with FLT3 -ITD mutation under treatment with midostaurin

Blood (2021) 137 (22): 3093–3104.

DOI: https://doi.org/10.1182/blood.2020007626

Published: 2021

Includes: Supplemental data

Journal Articles

AL patients don’t dare go without dara

Angela Dispenzieri

Blood (2020) 135 (18): 1509–1510.

DOI: https://doi.org/10.1182/blood.2020005436

Published: 2020

Journal Articles

Pathobiology and treatment of lymphomatoid granulomatosis, a rare EBV-driven disorder

Christopher Melani, Elaine S. Jaffe, Wyndham H. Wilson

Blood (2020) 135 (16): 1344–1352.

DOI: https://doi.org/10.1182/blood.2019000933

Published: 2020

Journal Articles

Estimation of Total Costs in Pediatric and Young Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia Receiving Tisagenlecleucel from a US Hospital's Perspective

Hongbo Yang, Yanni Hao, PhD, Cynthia Z. Qi, MBA, Xinglei Chai, PhD, Eric Q Wu

Blood (2019) 134 (Supplement_1): 4723.

DOI: https://doi.org/10.1182/blood-2019-129215

Published: 2019

Journal Articles

The Burden of Relapsed/Refractory Multiple Myeloma: An Indirect Comparison of Health-Related Quality of Life Burden across Different Types of Advanced Cancers at Baseline and after Treatment Based on HORIZON (OP-106) Study of Melflufen Plus Dexamethasone

Paul G. Richardson, MD, Alessandra Larocca, Xavier Leleu, MD PhD, Albert Oriol, MD, Agne Paner, MD, Paula Rodriguez Otero, Cyrille Touzeau, MD, Adrián Alegre Amor, MD, Christopher Maisel, MD, María-Victoria Mateos, MD PhD, Amitabha Mazumder, MD, Peter Strang, MD, Oskar Öhman, MSc, Johan Harmenberg, MD PhD, Stojan Zavisic, Joan Bladé, MD

Blood (2019) 134 (Supplement_1): 3487.

DOI: https://doi.org/10.1182/blood-2019-124832

Published: 2019

Journal Articles

Evolution in Practice Patterns and Differences Among Experts and Community Healthcare Providers in the Treatment of Patients with Chronic Lymphocytic Leukemia

Bing-E Xu, PhD, Kristen M Rosenthal, PhD, Krista Marcello, BA, Farrukh T. Awan, MD, Steven Coutre, MD, Nicole Lamanna, MD, Jeff P. Sharman, MD, Timothy A Quill, PhD, Kevin L Obholz, PhD, Andrew D. Zelenetz, MD PhD

Blood (2019) 134 (Supplement_1): 4724.

DOI: https://doi.org/10.1182/blood-2019-129266

Published: 2019

Journal Articles

The Role of Monitoring Complement Levels in Catastrophic Antiphospholipid Syndrome: A Case Series of 4 Patients

Lauren M Panebianco, MD, Teresa Gentile, MD PhD

Blood (2019) 134 (Supplement_1): 4872.

DOI: https://doi.org/10.1182/blood-2019-128297

Published: 2019

Journal Articles

A Matching-Adjusted Indirect Comparison of Nivolumab Versus Brentuximab Vedotin for Relapsed/Refractory Classical Hodgkin Lymphoma after Failure of Autologous Hematopoietic Cell Transplantation

Clara Chen, PhD BS, MS, Philippe Armand, MD PhD, Basia Rogula, Karissa Johnston, Derek Peterson, Joseph M Connors, MD, Greta Lozano-Ortega, MSc

Blood (2019) 134 (Supplement_1): 4761.

DOI: https://doi.org/10.1182/blood-2019-122302

Published: 2019

Journal Articles

Conventional Chemotherapy Treatment Induces Unique Patterns of Clonal Evolution in a North American Adult T Cell Leukemia/Lymphoma Cohort

Blood (2019) 134 (Supplement_1): 1551.

DOI: https://doi.org/10.1182/blood-2019-131107

Published: 2019

Journal Articles

Comparative Genomic Analyses Defines Shared and Unique Features of cHL and PMBL and New Mechanisms of Sensitivity to PD-1 Blockade

Blood (2019) 134 (Supplement_1): 1493.

DOI: https://doi.org/10.1182/blood-2019-131904

Published: 2019

Journal Articles

Potential Genetic and Immunologic Mechanisms of Therapeutic Resistance and Disease Progression in CNS Lymphoma Elucidated Via Whole Brain Autopsy Studies

David A. Solomon, MD, PhD, Huimin Geng, PhD, Raymond A. Sobel, MD, Lakshmi Subbaraj, B.S., Mazie Tsang, MD, James L. Rubenstein, MD PhD

Blood (2019) 134 (Supplement_1): 1494.

DOI: https://doi.org/10.1182/blood-2019-131302

Published: 2019

Journal Articles

Long-Term Follow-up Confirms Durability of Single-Agent Brentuximab Vedotin As Pre-Transplant Salvage for Classical Hodgkin Lymphoma

Alison J. Moskowitz, MD, Heiko Schoder, MD, Jisun Lee, Theresa Davey, MMSc, PA-C, Helen Hancock, ANP, Paul A. Hamlin, MD, Steven M. Horwitz, MD, Anita Kumar, MD, Matthew J Matasar, MD, Ariela Noy, MD, M. Lia Palomba, MD, Gunjan L. Shah, MDMS, Miguel-Angel Perales, MD, Craig S. Sauter, MD, David J. Straus, MD, Anas Younes, MD, Andrew D. Zelenetz, MD PhD, Joachim Yahalom, MD, Craig H. Moskowitz

Blood (2019) 134 (Supplement_1): 1555.

DOI: https://doi.org/10.1182/blood-2019-129364

Published: 2019

Journal Articles

Preliminary Clinical Results from a Phase 1 Study of ACTR707 in Combination with Rituximab in Subjects with Relapsed or Refractory CD20 + non-Hodgkin Lymphoma

Ian W. Flinn, MD PhD, Jason R. Westin, MD, Jonathon B. Cohen, MDMS, Luke P. Akard, MD, Samantha Jaglowski, MDMPH, Jessica Sachs, MD, Ann Ranger, PhD, Patricia Harris, MPH, Francis Payumo, BSc, MSc, Veronika Bachanova, MD PhD

Blood (2019) 134 (Supplement_1): 1587.

DOI: https://doi.org/10.1182/blood-2019-125995

Published: 2019

Journal Articles

Comparison of Outcomes after Early Hospital Discharge (EHD) Following Intensive Induction Vs. Post-Remission Chemotherapy for Adults with Acute Myeloid Leukemia (AML) and Other High-Grade Myeloid Neoplasms

Anna B. Halpern, MD, Nicholas P Howard, Megan Othus, PhD, Paul C. Hendrie, MD PhD, Nikita Vashi Baclig, MD MPH, Sarah A Buckley, MD, Mary-Elizabeth M. Percival, MD, Pamela S. Becker, MD PhD, Bart L. Scott, MD, Vivian G. Oehler, MD, Terry B. Gernsheimer, MD, Sioban B. Keel, MD, Johnnie Orozco, MD, Ryan D. Cassaday, MD, Andrei R Shustov, MD, Garrett Hartley, Verna L Welch, PhD MPH, Elihu H. Estey, MD, Roland B. Walter, MD PhD MS

Blood (2019) 134 (Supplement_1): 1317.

DOI: https://doi.org/10.1182/blood-2019-124586

Published: 2019

Journal Articles

Durable Remission and Long-Term Survival in Relapsed/Refractory (r/r) AML Patients Treated with Guadecitabine, Median Survival Not Reached for Responders after Long Term Follow up from Phase 2 Study of 103 Patients

Elizabeth A. Griffiths, MD, Hagop M. Kantarjian, MD, Casey L. O'Connell, MD, Karen W.L. Yee, MD, Wendy Stock, MD, Naval G. Daver, MD, Elias Jabbour, MD, Ellen K. Ritchie, MD, Jean-Pierre Issa, MD, Katherine J. Walsh, MD, David A. Rizzieri, MD, Scott D. Lunin, MD, Xiang Yao Su, PhD, Mohammad Azab, MD, Gail J. Roboz, MD

Blood (2019) 134 (Supplement_1): 1319.

DOI: https://doi.org/10.1182/blood-2019-131394

Published: 2019

Journal Articles

Durable Responses and Survival in High Risk AML and MDS Patients Treated with an Allogeneic Leukemia-Derived Dendritic Cell Vaccine

Luca L.G. Janssen, MD, Theresia M. Westers, PhD, Jeroen Rovers, MD PhD, Peter Valk, PhD, Jacqueline Cloos, PhD, Tanja D. de Gruijl, PhD, Arjan A. Van de Loosdrecht, MD PhD

Blood (2019) 134 (Supplement_1): 1381.

DOI: https://doi.org/10.1182/blood-2019-127881

Published: 2019

Journal Articles

A Modified CALGB-10403 in Hispanic Adolescent and Young Adults with Philadelphia -Negative Acute Lymphoblastic Leukemia: Promising Results Despite a High-Rate of Metabolic and Hepatic Toxicities

Juan Rangel-Patiño, MD, Alvaro Cabrero Garcia, Carolina Balderas-Delgado, MD, Lauro Fabian Amador, MD, Yvette Neme Yunes, Ana Cooke, MD, Adriana Rosas, Roberta Demichelis, MD

Blood (2019) 134 (Supplement_1): 1352.

DOI: https://doi.org/10.1182/blood-2019-126108

Published: 2019

Journal Articles

Somatic Mutation Profile Analyzed By Next-Generation Sequencing in Relapsed/Refractory Follicular Lymphoma Treated with Idelalisib

Blood (2019) 134 (Supplement_1): 1503.

DOI: https://doi.org/10.1182/blood-2019-126459

Published: 2019

Journal Articles

Procarbazine-Free Escalated Beacopdac in Frontline Therapy of Advanced Hodgkin Lymphoma Reduces Red Cell Transfusion Requirements and May Shorten Time to Menstrual Period Recovery Compared to Escalated Beacopp and Appears to be As Efficacious

Blood (2019) 134 (Supplement_1): 1564.

DOI: https://doi.org/10.1182/blood-2019-125256

Published: 2019

2 3 4 5

NARROW

Primary mediastinal Large B-cell Lymphoma

Clonal evolution of acute myeloid leukemia with FLT3 -ITD mutation under treatment with midostaurin

AL patients don’t dare go without dara

Pathobiology and treatment of lymphomatoid granulomatosis, a rare EBV-driven disorder

Estimation of Total Costs in Pediatric and Young Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia Receiving Tisagenlecleucel from a US Hospital's Perspective

The Burden of Relapsed/Refractory Multiple Myeloma: An Indirect Comparison of Health-Related Quality of Life Burden across Different Types of Advanced Cancers at Baseline and after Treatment Based on HORIZON (OP-106) Study of Melflufen Plus Dexamethasone

Evolution in Practice Patterns and Differences Among Experts and Community Healthcare Providers in the Treatment of Patients with Chronic Lymphocytic Leukemia

The Role of Monitoring Complement Levels in Catastrophic Antiphospholipid Syndrome: A Case Series of 4 Patients

A Matching-Adjusted Indirect Comparison of Nivolumab Versus Brentuximab Vedotin for Relapsed/Refractory Classical Hodgkin Lymphoma after Failure of Autologous Hematopoietic Cell Transplantation

Conventional Chemotherapy Treatment Induces Unique Patterns of Clonal Evolution in a North American Adult T Cell Leukemia/Lymphoma Cohort

Comparative Genomic Analyses Defines Shared and Unique Features of cHL and PMBL and New Mechanisms of Sensitivity to PD-1 Blockade

Potential Genetic and Immunologic Mechanisms of Therapeutic Resistance and Disease Progression in CNS Lymphoma Elucidated Via Whole Brain Autopsy Studies

Long-Term Follow-up Confirms Durability of Single-Agent Brentuximab Vedotin As Pre-Transplant Salvage for Classical Hodgkin Lymphoma

Preliminary Clinical Results from a Phase 1 Study of ACTR707 in Combination with Rituximab in Subjects with Relapsed or Refractory CD20 + non-Hodgkin Lymphoma

Comparison of Outcomes after Early Hospital Discharge (EHD) Following Intensive Induction Vs. Post-Remission Chemotherapy for Adults with Acute Myeloid Leukemia (AML) and Other High-Grade Myeloid Neoplasms

Durable Remission and Long-Term Survival in Relapsed/Refractory (r/r) AML Patients Treated with Guadecitabine, Median Survival Not Reached for Responders after Long Term Follow up from Phase 2 Study of 103 Patients

Durable Responses and Survival in High Risk AML and MDS Patients Treated with an Allogeneic Leukemia-Derived Dendritic Cell Vaccine

A Modified CALGB-10403 in Hispanic Adolescent and Young Adults with Philadelphia -Negative Acute Lymphoblastic Leukemia: Promising Results Despite a High-Rate of Metabolic and Hepatic Toxicities

Somatic Mutation Profile Analyzed By Next-Generation Sequencing in Relapsed/Refractory Follicular Lymphoma Treated with Idelalisib

Procarbazine-Free Escalated Beacopdac in Frontline Therapy of Advanced Hodgkin Lymphoma Reduces Red Cell Transfusion Requirements and May Shorten Time to Menstrual Period Recovery Compared to Escalated Beacopp and Appears to be As Efficacious

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only